Zantac Relaunches With New Name and Ingredient After Recall Due to Increased Cancer Risk

In April 2020, the Food and Drug Administration (FDA) issued a recall of all prescription and over-the-counter (OTC) versions of ranitidine, more commonly known as Zantac, due to an increased cancer risk. Recently, the medication relaunched with a new name and ingredient: Zantac 360 (famotidine). The oral tablet is available in two strengths (10 mg … Continue reading Zantac Relaunches With New Name and Ingredient After Recall Due to Increased Cancer Risk